ExploreWatchlistsPricing
  1. JP-listed companies
  2. Delta-Fly Pharma, Inc.
  3. Financials
  4. EBITDA

Delta-Fly Pharma, Inc. (4598)

Market cap
¥2.1B
P/E ratio
-1.2x
Delta-Fly Pharma develops cancer treatments using a unique "modular drug discovery" approach that builds new drugs from existing cancer-fighting compounds.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Mar 31, 2025-1,707+21.73%
Mar 31, 2024-1,402+6.68%
Mar 31, 2023-1,314+36.92%
Mar 31, 2022-960+12.89%
Mar 31, 2021-850-44.93%
Mar 31, 2020-1,544+160.99%
Mar 31, 2019-592+143.55%
Mar 31, 2018-243

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat